23 January 2023: Articles
Central Diabetes Insipidus in the Background of Lithium Use: Consider Central Causes Despite Nephrogenic as the Most Common
Unusual clinical course, Unexpected drug reaction
Jeffrey J. Li A* , Shirley Tan B , Takumi Kawashita B , Christian A. Tagle B , Farbod Farmand ADOI: 10.12659/AJCR.939034
Am J Case Rep 2023; 24:e939034
Figure 2. (A) Daily measurement of sodium concentration throughout the patient’s hospitalization. On Day 3, an infusion of Dextrose 5% was given as needed. On Day 8, Desmopressin trial 1 (4 µg DDAVP) was administered subcutaneously (SC), with additional doses of desmopressin (DDAVP) administered on an as needed basis. On Day 17, Desmopressin trial 2 (1 µg DDAVP) was given after an overnight water deprivation test, with further daily doses given as needed. (B) Daily measurement of urine output volume throughout the patient’s hospitalization. As needed DDAVP injections were given: 4 µg on Day 9, 4 µg on Day 10, 4 µg on Day 14, and 1 µg on Day 18.